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Modeling the burden of cardiovascular disease in Turkey
Introduction
According to the World Health Organization (WHO), cardio-
vascular diseases (CVD) are the leading cause of death globally, 
and were responsible for over 17 million deaths (about 31% of all 
deaths) in 2012. By 2030, CVD are projected to account for ap-
proximately 23.6 million deaths annually worldwide, surpassing by 
a huge margin the global burden of infectious diseases, nutritional 
disorders, and maternal conditions combined (1).
In 2010, ischemic heart disease (IHD) and cerebrovascular dis-
ease (CeVD) were reported as the first and second leading causes 
of premature deaths in Turkey. Each was responsible for estimated 
1.8 million and 1.2 million years of life lost (YLL) (2). Still, mortality 
rates from IHD and CeVD have been consistently declining since 
1994 and 2004, respectively (3). In addition, CVD are among the 
leading causes of lost disability-adjusted life years (DALYs), with 
IHD accounting for 2160 lost DALYs per year, and CeVD for 976 
DALYs (4).
Like other countries in the region and across the world, Tur-
key’s population of approximately 80 million is aging, caused in 
part by steadily decreasing mortality and fertility (5, 6). In addition, 
positive changes in availability of primary health care, economic 
growth, and immunization rates have contributed to an epidemio-
logical shift from communicable diseases and nutritional deficien-
cies toward noncommunicable diseases such as CVD (7, 8).
The rising prevalence of modifiable risk factors is also inti-
mately linked to the growing burden of chronic diseases, includ-
ing CVD. For example, several studies have reported high rates 
of overweight and obesity, low physical activity, hypertension, 
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dyslipidemia, and type 2 diabetes in the Turkish population (9-11). 
Inversely, epidemiological research has shown that CVD events 
are preventable through the modification, elimination, or avoid-
ance of one or several of these risk factors. For example, declining 
rates of CVD in some high-income countries have been attributed 
to population-wide prevention initiatives, and access to effective 
medical and pharmacological interventions (12).
Planning and implementing effective public policies to achieve 
these improvements relies on access to reliable and up-to-date 
information on the prevalence and economic burden of CVD in 
Turkey. To meet this need, this study (Part 1) estimates the preva-
lence, mortality, and economic burden of CVD, and forecasts the 
results out to 2035. A linked study (Part 2) estimates the health and 
economic impact of addressing modifiable risk factors for CVD.
Methods
The Conference Board of Canada developed an additive bur-
den of illness model that projects the prevalence and economic 
burden of CVD in Turkey out to 2035. The approach is similar to the 
model developed by Checkoway et al. (13) in “Research Methods in 
Occupational Epidemiology” as detailed later. The additive model 
assumes that when an individual has two or more risk factors, their 
increased risk (beyond the base risk) of developing IHD or stroke is 
the sum of the increased risks of each of the risk factors present.
Our model relies on population forecasts combined with the 
prevalence/incidence of CVD and modifiable risk factors, and 
estimated relative risks, to project the prevalence of CVD over 
time. Data presented in the next sections were used to create a 
forecast of the direct costs of treating CVD, while an indirect cost 
model was developed to project foregone earnings and reduced 
productivity due to illness.
Population model
The demographic forecast of the Turkish population is crucial 
to the analysis as it drives a significant portion of changes in dis-
ease prevalence over time. Population estimates and projections 
were obtained from the World Bank DataBank, and are based 
on total population and age distributions of the United Nations 
Population Division’s World Population Prospects (14). Popula-
tion growth in Turkey appears to be relatively linear (arithmetic 
increase) between 2016 and 2035.
Prevalence of cardiovascular disease and risk factors
In our study, CVD is broadly defined as IHD and CeVD, and 
model inputs were collected for both the conditions. According to 
various sources, 5.8% of Turkish males and 5% of females have a 
history of heart disease, while 1.7% of males and 2.2% of females 
have a history of stroke (15, 16).
Epidemiologic research has shown that CVD are partially pre-
ventable through the modification, elimination, or avoidance of 
modifiable risk factors, including hyperlipidemia, arterial hyperten-
sion, type 2 diabetes mellitus, tobacco smoking, overweight and 
obesity, physical inactivity, and low fruit and vegetable consump-
tion. Our model leverages prevalence rate estimates from a vari-
ety of sources, including the Chronic Diseases and Risk Factors 
Survey from the Ministry of Health, Ankara (see Appendix Table 1).
Relative risk of cardiovascular disease
Estimates for the relative risk of each condition with and with-
out a risk factor, or for different levels of exposure/intensity of a risk 
factor, were obtained from a review of the literature (see details in 
Appendix Table 2). This literature review included systematic re-
views examining the relationship between various modifiable and 
lifestyle risk factors and chronic conditions. Where a systematic 
review was not available to quantify the risk factor-condition rela-
tionship, other individual studies (of mostly observational design) 
were included.
Mortality rates
Data on number of deaths for IHD (ICD-10 codes: I20–I25) and 
CeVD (ICD-10 codes: I60–I69) came from WHO’s Mortality Data-
base (17). The case fatality rate is calculated as the number of 
deaths in 2013 (the most recent year for which data was avail-
able) divided by the prevalence in 2013 for each condition (see 
details in Appendix Table 3). In our model, the case fatality rate 
is assumed to remain constant over the forecast period for each 
age-sex group.
Estimating the base risk
In our study, the base risk is defined as the prevalence rate 
of a condition in the absence of any risk factor. It is important be-
cause the relative risk of each risk factor is added to the base risk 
in the model to forecast prevalence rates of IHD and CeVD from 
2016 to 2035. The additive model used in this report is as described 
by Checkoway et al. (13) in “Research Methods in Occupational 
Epidemiology.” It implies that in the prevalence of several concur-
ring risk factors, the relative risk is assumed to be where n is the 
total number of concurrent risk factors.
∑ Ri
i=0
n
R = – (n–1)
The additive model assumes that when an individual has two 
or more risk factors, his or her increased risk (beyond the base 
risk) of developing a chronic condition is the sum of the increased 
risks of each of the risk factors he or she has. For example, if 
smoking raises the chance of developing cancer by 10 percentage 
points, and lack of physical activity by 5 percentage points, then 
the additive model assumes that a person who both smokes and is 
physically inactive will have a 15 percentage-point increased risk 
of developing cancer. Because base risks are not documented in 
the literature, we estimated them using data on the prevalence of 
risk factors combined with relative risk estimates from the litera-
ture (see Appendix Table 4).
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Forecasting the prevalence of cardiovascular disease
A forecast of the prevalence of CVD by age and sex was gen-
erated by using our base risk estimates, combined with our rela-
tive risk estimates and our population forecasts. The number of 
acute incident (hospitalized) cases of IHD and CeVD in Turkey was 
estimated by applying a Centers for Disease Control and Preven-
tion (CDC) statistic on the proportion of individuals with IHD and 
CeVD who are hospitalized per year due to their condition (18, 19), 
to the prevalence of each condition in Turkey. This proportion of 
incident (hospitalized) cases is 13.4% for individuals diagnosed 
with IHD and 15.9% for CeVD. In our model, the prevalence rate 
of CVD and modifiable risk factors as well as the relative risk esti-
mates were assumed to remain constant over the forecast period 
of 2015–2035.
From prevalence to economic burden estimates
A projection of the economic burden of CVD was developed by 
leveraging our prevalence forecasts, combined with disease cost 
data and CVD mortality rates.
Direct costs
Direct costs refer to costs directly related to the detection, 
treatment, and rehabilitation of a disease. The average cost per 
hospitalized case of IHD was calculated from a sample dataset 
of 2728 admitted cases (ICD I20–I25) to the University of Health 
Sciences Türkiye Yüksek İhtisas Hospital reimbursed between 
January and March 2016 by the Social Security Institution [Sosyal 
Güvenlik Kurumu (SGK)] (20). The average cost per hospitalized 
case of CeVD was obtained from the literature (21). An adjustment 
was subsequently applied to account for disease maintenance 
costs, estimated as a share of hospitalization costs presented 
in work by Hermus et al. (22). More specifically, the management 
costs represent the annual cost of controlling (or managing) the 
condition, excluding hospitalization costs. This includes visits 
to a family doctor, and medications needed to treat the disease 
that are separate from an actual visit to the hospital due to an 
acute event, which were estimated at 27.5% of the cost of hospi-
talizations for IHD and 21% for CeVD (22). In our study, prevalent 
non-hospitalized cases of IHD and CeVD were modeled to incur 
maintenance costs only (US$735 and US$352, respectively), while 
acute incident hospitalized cases included both the hospitaliza-
tion and maintenance costs (totaling US$3411 for IHD and $2030 
for CeVD) (Table 1).
The adjusted costs per case was then converted from Turk-
ish Lira (TRY) to United States dollar (US$) using the Organisation 
for Economic Co-Operation and Development (OECD) purchasing 
power parity (PPP) adjusted exchange rate for 2014 of 1.163. The 
PPP is often used in international economic analyzes as an alter-
native to market rates, which are highly volatile and vary over time 
(23). The OECD also states that PPPs are much more stable, and 
represent exchange rates that are relative to the ratio of prices 
(in national currencies) for the same basket of goods or services 
in different countries (24). Based on expert opinion, inflation rates 
were not applied to the cost per case over the forecast period be-
cause the cost of health care services has remained stable in the 
last decade in Turkey, and is not expected to increase in the near 
future. The resulting economic burden of CVD in Turkey is expect-
ed to follow a linear increase as it is calculated as a function of 
prevalence (which increases linearly with population) multiplied 
by the average cost per case.
Indirect costs
Indirect costs in economic analyses are typically calculated 
as the value of foregone income lost due to disease. These costs 
can arise for several reasons, and in our model, they include costs 
from premature mortality, early retirement, and hospitalizations. 
To calculate the foregone earnings from CVD over patients’ life-
time, the human capital approach was used, we and leveraged ex-
isting data and estimates from the literature (25-28). The value of 
time lost from work is measured by foregone earnings calculated 
as average earnings, adjusted by the participation rate and un-
employment rate, over the relevant period within the working life 
of an individual from ages 15 to 65 years inclusive (see Appendix 
Table 5 for more details).
Results
Prevalence and incidence of cardiovascular disease
We estimated that in 2016, 3.4 million Turks were living with 
CVD, including 2.5 million individuals affected by IHD and 0.9 mil-
lion by CeVD. Out of this prevalence, the number of acute incident 
(hospitalized) cases in 2016 was estimated at 324.242 for IHD and 
141.359 for CeVD. The prevalence of CVD is projected to increase 
to 4.2 million adults by 2025, and to 5.4 million by 2035, which rep-
resents a 26.0% and 58.1% growth in prevalence respectively 
compared to 2016 (Fig. 1). This increase is anticipated to be driven 
by both IHD and CeVD, although the later condition will grow at a 
greater pace than the former (67.1% vs. 54.7% between 2016 and 
2035). Within this broader prevalence, the number of incident cas-
Table 1. Average direct cost per case
 Hospitalization cost (US$) Maintenance cost (US$) Total cost (US$)
Ischemic heart disease $2,675 $735 $3,411
Cerebrovascular disease $1,678 $352 $2,030
US$: United States Dollar
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es is expected to increase at a similar rate, reaching 516,473 new 
cases of IHD and 244.043 new cases of CeVD by 2035.
In 2016, more than half of the overall prevalence of CVD was 
found to occur between the ages of 55-74 years (55.5%), followed 
by 35-54 years (31.1%). A smaller proportion of cases were expect-
ed for the older age group of 75 years and above (10.1%), and even 
fewer for the 25-34 age group (3.3%). By 2035, the growing preva-
lence of CVD will be proportionately accompanied by more cases 
of heart disease and stroke occurring in older age groups. For ex-
ample, 14.2% of CVD cases are projected to occur in adults aged 75 
years and above by 2035, which represents a 40.3% increase com-
pared to 2016. Inversely, adults aged 35-54 years old will represent 
a diminishing proportion of affected individuals (Fig. 2).
Cardiovascular disease mortality
We estimated that 100,430 deaths were due to CVD in 2016, 
with 60,963 deaths attributable to IHD and 39,468 to CeVD. By 2035, 
the number of deaths is expected to nearly double to 194,702, with 
CeVD deaths increasing at a slightly steeper rate compared to that 
of IHD, with 78,131 and 116,572 deaths, respectively. In 2016, the 
majority of deaths were expected to occur in the older age group 
of 75 years and above, followed closely by adults aged 55-74 years 
old (56.0% and 35.6%, respectively). It is also expected that the 
75 and older age group will experience a steeper increase in the 
number of CVD deaths over time (Fig. 3).
The economic burden of cardiovascular disease
In 2016, the economic burden of CVD in Turkey, including direct 
health-care costs and indirect costs from lost productivity, was es-
timated at US$10.2 billion. Most of this burden (US$5.9 billion) was 
associated with IHD, while CeVD costs were estimated at US$4.2 
billion. Direct health-care costs, estimated at US$3.4 billion in 2016, 
were responsible for one-third of the overall economic burden of 
CVD, while indirect costs made up the other two-thirds at US$6.8 
billion. The burden of CVD in Turkey is projected to increase by 
40% by 2025, reaching US$14.2 billion. By 2035, direct and indirect 
costs are expected to total US$19.4 billion, nearly doubling since 
2016. Furthermore, direct costs are forecast to grow at a slower 
rate than indirect costs, reaching US$5.4 billion and US$13.9 billion 
respectively by the end of the forecast period (Fig. 4).
Discussion
Using a burden-of-disease model, we estimated the current 
and future burden of CVD in Turkey. The economic burden is ap-
proached from two perspectives: the first is the impact on the pub-
lic health-care system (direct costs), and the second is the impact 
on society from lost productivity (indirect costs). We projected 
that the prevalence of CVD would grow from 3.4 million in 2016 
to 5.3 million cases by 2035, while the economic burden would al-
most double from US$10.2 billion to US$19.4 billion. This increase 
is largely driven by demographic changes and more specifically 
by the anticipated aging of the Turkish population over the next 20 
years, which is expected to shift the proportion of CVD cases even 
more toward older age groups.
Our results complement the existing literature on the burden of 
disease in Turkey, which shows that CVD are one of the most im-
portant causes of premature mortality and disability in the country 
(2, 4, 29). According to the WHO data, IHD and CeVD are among 
Figure 1. Prevalence of cardiovascular disease by year, 2016-2035
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Figure 2. Distribution of cardiovascular disease prevalence by age 
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Figure 4. Economic burden of cardiovascular disease, 2016-2035
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the main causes of DALYs, contributing to 2160 and 976 lost DALYs, 
respectively (4). In 2003, it was estimated IHD cost the European 
economy €49 billion a year, which corresponded to around 2.6% 
of total health-care expenditure (30). Although our study did not 
compare the burden of CVD with other conditions, it reaffirms that 
CVD is of concern in Turkey, and will increase at a steep rate over 
the next 20 years.
The growing burden of CVD projected in our study is also indi-
rectly aligned with the observation that Turkey is experiencing a 
major epidemiological transition where the main causes of mor-
tality are shifting away from infectious diseases and nutritional 
deficiencies toward noncommunicable diseases (31). Along with 
improvements in the health-care system, other factors are influ-
encing this shift. For example, urbanization is leading to important 
lifestyle changes related to diet and sedentary behavior. Rising 
immunization rates, improved sanitation, and economic growth 
are also contributing to the shift toward chronic and noncommu-
nicable diseases (31).
Turkey’s epidemiological transition is also contributing to im-
portant demographic changes, characterized by an increasingly 
greater distribution of the population represented in older age 
groups. Indeed, population projections from the World Bank Da-
taBank show the country’s population will age significantly within 
the next two decades (14). The share of adults aged 65 years and 
above is expected to almost double from 7.5% in 2015 to 13.9% in 
2035. Likewise, the share of adults aged between 50 and 64 years 
will increase from 13.5% in 2015 to 18.3% in 2035.
We believe this demographic shift toward an older age pyramid 
is largely responsible for the projected increase in CVD burden 
over time reported in our study. As the population continues to in-
crease and age over the next two decades, so will the prevalence, 
deaths, and costs associated with CVD. This growing burden of 
disease will likely create significant pressure on the public health-
care system in the form of direct health-care costs, as well as on 
society in the form of lost productivity.
Indeed, the composition and financing structure of health-
care systems largely impact the burden chronic diseases place 
on governments, private insurers, and individuals. The Turkish 
national health-care system is comprised of a mix of public and 
private institutions. Universal coverage is provided under the Uni-
versal Health Insurance (Genel Sağlık Sigortası) system, which 
insures individuals registered with the Social Security Institution 
(Sosyal Güvenlik Kurumu). The state of the health-care system in 
Turkey has improved in recent years due to changes implemented 
as part of the Health Transformation Program (HTP), which tackled 
legislative, governance, efficiency, and quality improvements (32).
In light of the projected growing burden of CVD in the next 20 
years, the Turkish government has interest in increasing public 
health efforts to address the most important modifiable risk fac-
tors, including hypertension, dyslipidemia, tobacco smoking, type 
2 diabetes, obesity, and overweight. This is especially important in 
the context of Turkey’s economic development, which could lead 
to inflation of the cost of health-care services, and further contrib-
ute to the growing economic burden of CVD incurred by govern-
ment. By adding to the knowledge base on the current and future 
burden of CVD in Turkey, we hope our study will contribute to the 
movement toward greater public health efforts and increased ac-
cess to effective treatments to address modifiable risk factors.
Study limitations
Our study makes use of the best available information to 
forecast the prevalence and economic burden of CVD in Turkey. 
While every effort was made to maximize the accuracy of these 
forecasts, certain limitations in the data sources and modeling 
assumptions are worth noting. New estimates of the average 
cost per case of IHD and CeVD hospitalizations recently became 
available. These new cost figures are slightly higher than the ones 
used in our model; therefore, we may be underestimating the true 
economic burden of CVD in Turkey. Furthermore, assumptions on 
the share of hospitalized and non-hospitalized cases were used to 
derive CVD incidence from the overall prevalence of the condition.
In terms of our modeling approach, we used an additive model 
that assumed an increased risk of CVD for every risk factor pres-
ent in the population. This could lead to an overestimation of the 
true overall risk in the event that specific risk factors moderate 
one another when present in combination. An alternative to the 
additive model is the multiplicative model, which is mostly used in 
studies where risk factors are believed to act as effect modifiers 
for the relationship between another risk factor and the risk of the 
condition. Multiplicative models are believed to be more relevant 
in disease etiology studies, while additive models are most often 
used (and are also easier to interpret) when quantifying the im-
pact of public health measures to reduce disease frequency (33).
In our study, the prevalence of risk factors is assumed to re-
main constant over the forecast period, although the longitudinal 
Turkey Adult Risk Factor Study (TEKHARF) could have been used to 
derive historical data on risk factor progression in Turkey (34). For 
example, some risk factors such as obesity and diabetes may see 
an increase in the future, which would impact the projected preva-
lence of CVD over the forecast period. Inversely, some risk factors 
such as tobacco smoking may see a decrease in future years, 
which could lessen the burden of CVD in Turkey. Lastly, our indirect 
cost model was limited to costs due to premature mortality, early 
retirement, and hospitalizations, and did not consider other costs 
such as payments made by the Social Security Institution to rela-
tives of severely disabled patients after a Rankin 4 stroke episode.
Conclusion
CVD, and more specifically, IHD and CeVD are two important 
causes of morbidity, premature mortality, and disability in Turkey. 
Our study confirms that the current burden of CVD is significant, 
and that it is projected to increase at a steep rate over the next 
two decades due in large part to aging of the population. This 
growing burden of disease will likely create significant pressure 
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on the public health-care system in the form of direct health-care 
costs, as well as on society in the form of lost productivity. Efforts 
to address the key modifiable risk factors for CVD and to increase 
access to effective treatment are therefore essential to ensure the 
sustainability of the Turkish health-care system over time.
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